5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A systematic review of the therapeutic effects of resveratrol in combination with 5-fluorouracil during colorectal cancer treatment: with a special focus on the oxidant, apoptotic, and anti-inflammatory activities

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          5-fluorouracil (5-FU), an effective chemotherapy drug, is commonly applied for colorectal cancer treatment. Nevertheless, its toxicity to normal tissues and the development of tumor resistance are the main obstacles to successful cancer chemotherapy and hence, its clinical application is limited. The use of resveratrol can increase 5-FU-induced cytotoxicity and mitigate the unwanted adverse effects. This study aimed to review the potential therapeutic effects of resveratrol in combination with 5-FU against colorectal cancer.

          Methods

          According to the PRISMA guideline, a comprehensive systematic search was carried out for the identification of relevant literature in four electronic databases of PubMed, Web of Science, Embase, and Scopus up to May 2021 using a pre-defined set of keywords in their titles and abstracts. We screened 282 studies in accordance with our inclusion and exclusion criteria. Thirteen articles were finally included in this systematic review.

          Results

          The in vitro findings showed that proliferation inhibition of colorectal cancer cells in the groups treated by 5-FU was remarkably higher than the untreated groups and the co-administration of resveratrol remarkably increased cytotoxicity induced by 5-FU. The in vivo results demonstrated a decrease in tumor growth of mice treated by 5-FU than the untreated group and a dramatic decrease was observed following combined treatment of resveratrol and 5-FU. It was also found that 5-FU alone and combined with resveratrol could regulate the cell cycle profile of colorectal cancer cells. Moreover, this chemotherapeutic agent induced the biochemical and histopathological changes in the cancerous cells/tissues and these alterations were synergized by resveratrol co-administration (for most of the cases), except for the inflammatory mediators.

          Conclusion

          The results obtained from this systematic review demonstrated that co-administration of resveratrol could sensitize the colorectal cancer cells to 5-FU treatment via various mechanisms, including regulation of cell cycle distribution, oxidant, apoptosis, anti-inflammatory effects.

          Related collections

          Most cited references130

          • Record: found
          • Abstract: found
          • Article: not found

          Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

          This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.

              Radiotherapy plays a central part in curing cancer. For decades, most research on improving treatment outcomes has focused on modulating radiation-induced biological effects on cancer cells. Recently, we have better understood that components within the tumour microenvironment have pivotal roles in determining treatment outcomes. In this Review, we describe vascular, stromal and immunological changes that are induced in the tumour microenvironment by irradiation and discuss how these changes may promote radioresistance and tumour recurrence. We also highlight how this knowledge is guiding the development of new treatment paradigms in which biologically targeted agents will be combined with radiotherapy.
                Bookmark

                Author and article information

                Contributors
                hamed_parto@yahoo.com
                farhood-b@kaums.ac.ir , bffarhood@gmail.com
                Journal
                Cancer Cell Int
                Cancer Cell Int
                Cancer Cell International
                BioMed Central (London )
                1475-2867
                2 April 2022
                2 April 2022
                2022
                : 22
                : 142
                Affiliations
                [1 ]GRID grid.411259.a, ISNI 0000 0000 9286 0323, Radiation Sciences Research Center (RSRC), , AJA University of Medical Sciences, ; Tehran, Iran
                [2 ]GRID grid.411874.f, ISNI 0000 0004 0571 1549, Department of Radiotherapy and Oncology, , Razi Hospital, Guilan University of Medical Sciences, ; Rasht, Iran
                [3 ]GRID grid.412328.e, ISNI 0000 0004 0610 7204, Department of Medical Physics and Radiological Sciences, Faculty of Paramedicine, , Sabzevar University of Medical Sciences, ; Sabzevar, Iran
                [4 ]GRID grid.486769.2, ISNI 0000 0004 0384 8779, Department of Allied Medical Sciences, , Semnan University of Medical Sciences, ; Semnan, Iran
                [5 ]GRID grid.412888.f, ISNI 0000 0001 2174 8913, Medical Radiation Sciences Research Team, , Tabriz University of Medical Science, ; Tabriz, Iran
                [6 ]GRID grid.411495.c, ISNI 0000 0004 0421 4102, Department of Radiology Technology, Faculty of Paramedical Sciences, , Babol University of Medical Sciences, ; Babol, Iran
                [7 ]GRID grid.411705.6, ISNI 0000 0001 0166 0922, Department of Medical Physics, , Tehran University of Medical Sciences, ; Tehran, Iran
                [8 ]GRID grid.411746.1, ISNI 0000 0004 4911 7066, Radiation Biology Research Center, , Iran University of Medical Sciences, ; Tehran, Iran
                [9 ]GRID grid.444768.d, ISNI 0000 0004 0612 1049, Trauma Research Center, , Kashan University of Medical Sciences, ; Kashan, Iran
                [10 ]GRID grid.444768.d, ISNI 0000 0004 0612 1049, Department of Medical Physics and Radiology, Faculty of Paramedical Sciences, , Kashan University of Medical Sciences, ; Kashan, Iran
                Author information
                http://orcid.org/0000-0003-2290-7220
                Article
                2561
                10.1186/s12935-022-02561-7
                8976963
                35366874
                7dc7ee9d-fac1-4d67-968c-33783ee605f2
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 1 October 2021
                : 27 March 2022
                Categories
                Review
                Custom metadata
                © The Author(s) 2022

                Oncology & Radiotherapy
                colorectal cancer,chemotherapy,5-fluorouracil,resveratrol,systemic review
                Oncology & Radiotherapy
                colorectal cancer, chemotherapy, 5-fluorouracil, resveratrol, systemic review

                Comments

                Comment on this article